ALKS Alkermes Plc

Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 25th Annual Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 25th Annual Healthcare Conference on Tuesday, Nov. 8, 2016, at 9:30 a.m. MT (11:30 a.m. ET/4:30 p.m. GMT) from The Phoenician in Scottsdale, AZ. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

EN
01/11/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alkermes Plc

Alkermes, Inc.: Update to credit analysis

Alkermes credit profile reflects its modest financial leverage and strong liquidity, offset by revenue concentration in three neuroscience-based products and approaching generic competition.

Moody's affirms Alkermes' Ba3 CFR, outlook stable

Moody's Investors Service ("Moody's") affirmed the ratings of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes"). The affirmed ratings include the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, and the Ba3 senior secured term loan rating. There is no chang...

Alkermes, Inc.: Update to credit analysis

Our credit view of Alkermes reflects its good growth prospects on core products including Vivitrol, Aristada, and Lybalvi constrained by its pipeline execution and commercialization risk.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 26, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch